ScholarIQanswers from OpenAlex
Bloomberg (United States)
InstitutionResearch output, impact & collaborations
Bloomberg (United States) is a institution indexed in ScholarIQ from OpenAlex.
What is known about Bloomberg (United States)?
ScholarIQrecord summary
Bloomberg (United States) is a research organisation in New York, US. OpenAlex records 6,044 works and 772,734 citations for it. 1,069 researchers list it as their most recent affiliation.
How many works does Bloomberg (United States) have?
ScholarIQindexed works
Bloomberg (United States) has 6,044 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Bloomberg (United States) have?
ScholarIQcitation count
Bloomberg (United States) has 772,734 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Bloomberg (United States)?
ScholarIQresearcher count
Bloomberg (United States) has 1,069 researchers in the ScholarIQ index.
What is the average h-index at Bloomberg (United States)?
ScholarIQavg h-index
Bloomberg (United States) has an average h-index of 77.9 in OpenAlex.
What is the ROR of Bloomberg (United States)?
ScholarIQror
The ROR for Bloomberg (United States) is on the source record.
What is the OpenAlex record for Bloomberg (United States)?
ScholarIQopenalex
The OpenAlex for Bloomberg (United States) is on the source record.
What is the Wikidata of Bloomberg (United States)?
ScholarIQwikidata
The Wikidata for Bloomberg (United States) is on the source record.
Who are the most-cited researchers behind Bloomberg (United States)?
ScholarIQtop researchers by citations
What are the most-cited papers on Bloomberg (United States)?
ScholarIQmost cited works
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer, Scott Gettinger, David C. Smith, David F. McDermott, John D. Powderly, Richard D. Carvajal, Jeffrey A. Sosman, Michael B. Atkins, Philip D. Leming, David R. Spigel, Scott Antonia, Leora Horn, Charles G. Drake, Drew M. Pardoll, Lieping Chen, William H. Sharfman, Robert A. Anders, Janis M. Taube, Tracee L. McMiller, Haiying Xu, Alan J. Korman, Maria Jure–Kunkel, Shruti Agrawal, D. G. McDonald, Georgia Kollia, Ashok Gupta, Jon M. Wigginton, Mario Sznol
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinéad Cuffe, Mary O’Brien, Suman Rao, Katsuyuki Hotta, Melanie A. Leiby, Gregory M. Lubiniecki, Yue Shentu, Reshma Rangwala, Julie R. Brahmer
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Dung T. Le, Jennifer N. Uram, Hao Wang, Bjarne R. Bartlett, Holly Kemberling, Aleksandra Eyring, Andrew D. Skora, Brandon Luber, Nilofer S. Azad, Dan Laheru, Barbara Biedrzycki, Ross C. Donehower, Atif Zaheer, George A. Fisher, Todd S. Crocenzi, James J. Lee, Steven M. Duffy, Richard M. Goldberg, Albert de la Chapelle, Minori Koshiji, Feriyl Bhaijee, Thomas Huebner, Ralph H. Hruban, Laura D. Wood, Nathan Cuka, Drew M. Pardoll, Nickolas Papadopoulos, Kenneth W. Kinzler, Shibin Zhou, Toby C. Cornish, Janis M. Taube, Robert A. Anders, James R. Eshleman, Bert Vogelstein, Luis A. Díaz
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
H. Borghaei, L. Paz-Ares, Leora Horn, David R. Spigel, Martin Steins, Neal Ready, Laura Q.M. Chow, Everett E. Vokes, Enriqueta Felip, Esther Holgado, Fabrice Barlési, Martin Kohlhäufl, Óscar Arrieta, M. Burgio, Jérôme Fayette, H. Lena, Elena Poddubskaya, David E. Gerber, Scott Gettinger, Charles M. Rudin, Naiyer A. Rizvi, Lucio Crinò, George R. Blumenschein, Scott Antonia, Cécile Dorange, Christopher Harbison, F. Graf Finckenstein, Julie R. Brahmer
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Julie R. Brahmer, Karen L. Reckamp, Paul Baas, Lucio Crinò, Wilfried Eberhardt, Elena Poddubskaya, Scott Antonia, Adam Płużański, Everett E. Vokes, Esther Holgado, David Waterhouse, Neal Ready, Justin F. Gainor, Osvaldo Arén Frontera, Libor Havel, Martin Steins, Marina Chiara Garassino, Joachim G.J.V. Aerts, Manuel Dómine, Luis Paz‐Ares, Martin Reck, Christine Baudelet, Christopher Harbison, Brian Lestini, David R. Spigel
Who collaborates most closely around Bloomberg (United States)?
ScholarIQco-authorship network
United States
100%
MOST FREQUENT PARTNER INSTITUTIONS
How much of the research on Bloomberg (United States) is open access?
ScholarIQopen access share
92%OPEN ACCESS